Javlor (Vinflunine)

• Vinflunine is employed in the treatment of urothelial carcinoma, a cancer of the urinary tract.
• Advanced or metastatic urothelial carcinoma: provides a therapeutic option after failure of platinum‑based chemotherapy to achieve disease control, potentially extending progression‑free survival and offering an additional line of therapy.
• Platinum‑refractory urothelial carcinoma: serves as a later‑line treatment when standard platinum regimens are no longer effective, giving clinicians an alternative antineoplastic strategy.

• Vinflunine binds to tubulin at the vinca binding site, preventing microtubule polymerisation and destabilising the mitotic spindle. This inhibition of microtubule dynamics arrests cells in the G2/M phase of the cell cycle, leading to apoptosis of rapidly dividing cancer cells.

Vinflunine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Neutropenia: reduced neutrophil count increasing infection risk.
• Constipation: decreased bowel motility causing discomfort.
• Nausea and vomiting: gastrointestinal upset often requiring anti‑emetics.
• Fatigue: persistent tiredness affecting daily activities.
• Alopecia: hair loss that may be temporary.

Serious or Rare Side Effects

• Febrile neutropenia: fever with low neutrophils requiring urgent care.
• Severe hemorrhage: bleeding complications due to platelet suppression.
• Hepatic toxicity: elevated liver enzymes indicating liver injury.
• Renal impairment: decreased kidney function necessitating monitoring.
• Anaphylactic reactions: rare severe allergic responses needing immediate treatment.

• Vinflunine requires careful monitoring and specific safety measures before and during therapy.
• Monitor blood counts: perform regular complete blood counts to detect neutropenia or anemia.
• Assess renal function: evaluate creatinine clearance prior to each infusion.
• Evaluate hepatic function: check liver enzymes and bilirubin levels regularly.
• Avoid use in severe neutropenia: do not administer if absolute neutrophil count is critically low.
• Use with caution in elderly patients: consider dose adjustments and close observation.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the solution.

Vinflunine can interact with other medicines, altering its safety or effectiveness.

Major Interactions (Avoid)

• Concurrent myelosuppressive chemotherapy: may exacerbate bone‑marrow suppression.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase vinflunine exposure and toxicity.
• Live vaccines: heightened risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely)

• Moderate CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce vinflunine plasma levels.
• Antiemetics such as ondansetron: potential QT‑interval prolongation, monitor ECG.
• Warfarin: possible alteration of INR, require regular coagulation monitoring.